Overview of management of atrial fibrillation in symptomatic elderly patients: Pharmacologic therapy versus AV node ablation

David John Bradley, W. K. Shen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Atrial fibrillation is an abnormal heart rhythm affecting the upper chambers of the heart in which uncoordinated electrical depolarizations lead to ineffective contractions. Approximately five million patients in the US have atrial fibrillation, and this number is expected to double to 10 million over the next 30 years. Advancing age is a major risk factor for the development of atrial fibrillation; new cases of atrial fibrillation are diagnosed in men over age 80 at the rate of 2% per year. Although several drugs are available for management of atrial fibrillation, the efficacy of these drugs may be limited in elderly patients. In this review, we provide an overview of management of atrial fibrillation, with special emphasis on pharmacologic therapy versus arteriovenous (AV) node ablation in symptomatic elderly patients.

Original languageEnglish (US)
Pages (from-to)284-287
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume81
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Atrial Fibrillation
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{f56432ec23204a1fbfa1d5683dac3d5f,
title = "Overview of management of atrial fibrillation in symptomatic elderly patients: Pharmacologic therapy versus AV node ablation",
abstract = "Atrial fibrillation is an abnormal heart rhythm affecting the upper chambers of the heart in which uncoordinated electrical depolarizations lead to ineffective contractions. Approximately five million patients in the US have atrial fibrillation, and this number is expected to double to 10 million over the next 30 years. Advancing age is a major risk factor for the development of atrial fibrillation; new cases of atrial fibrillation are diagnosed in men over age 80 at the rate of 2{\%} per year. Although several drugs are available for management of atrial fibrillation, the efficacy of these drugs may be limited in elderly patients. In this review, we provide an overview of management of atrial fibrillation, with special emphasis on pharmacologic therapy versus arteriovenous (AV) node ablation in symptomatic elderly patients.",
author = "Bradley, {David John} and Shen, {W. K.}",
year = "2007",
month = "2",
doi = "10.1038/sj.clpt.6100062",
language = "English (US)",
volume = "81",
pages = "284--287",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Overview of management of atrial fibrillation in symptomatic elderly patients

T2 - Pharmacologic therapy versus AV node ablation

AU - Bradley, David John

AU - Shen, W. K.

PY - 2007/2

Y1 - 2007/2

N2 - Atrial fibrillation is an abnormal heart rhythm affecting the upper chambers of the heart in which uncoordinated electrical depolarizations lead to ineffective contractions. Approximately five million patients in the US have atrial fibrillation, and this number is expected to double to 10 million over the next 30 years. Advancing age is a major risk factor for the development of atrial fibrillation; new cases of atrial fibrillation are diagnosed in men over age 80 at the rate of 2% per year. Although several drugs are available for management of atrial fibrillation, the efficacy of these drugs may be limited in elderly patients. In this review, we provide an overview of management of atrial fibrillation, with special emphasis on pharmacologic therapy versus arteriovenous (AV) node ablation in symptomatic elderly patients.

AB - Atrial fibrillation is an abnormal heart rhythm affecting the upper chambers of the heart in which uncoordinated electrical depolarizations lead to ineffective contractions. Approximately five million patients in the US have atrial fibrillation, and this number is expected to double to 10 million over the next 30 years. Advancing age is a major risk factor for the development of atrial fibrillation; new cases of atrial fibrillation are diagnosed in men over age 80 at the rate of 2% per year. Although several drugs are available for management of atrial fibrillation, the efficacy of these drugs may be limited in elderly patients. In this review, we provide an overview of management of atrial fibrillation, with special emphasis on pharmacologic therapy versus arteriovenous (AV) node ablation in symptomatic elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=33846600536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846600536&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100062

DO - 10.1038/sj.clpt.6100062

M3 - Article

C2 - 17259952

AN - SCOPUS:33846600536

VL - 81

SP - 284

EP - 287

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -